Literature DB >> 29697436

Extended depth of focus intraocular lenses for presbyopia.

Sruti S Akella1, Viral V Juthani.   

Abstract

PURPOSE OF REVIEW: To summarize the various extended depth of focus (EDOF) intraocular lenses currently available to patients and to describe visual outcomes and patient satisfaction. RECENT
FINDINGS: EDOF lenses are a relatively new option for presbyopic correction. Preliminary studies show high levels of spectacle independence and patient satisfaction. The only United States Federal Drug Administration-approved intraocular lens currently on market is the TECNIS Symfony (Johnson and Johnson Vision, Jacksonville, FL).
SUMMARY: Early studies show that EDOF lenses may provide satisfactory near and intermediate vision with reduced incidence of haloes and glares often noted by patients implanted with multifocal lenses. Results are promising, but limited.

Entities:  

Mesh:

Year:  2018        PMID: 29697436     DOI: 10.1097/ICU.0000000000000490

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  19 in total

1.  Bias of near-infrared light in evaluation of patients implanted with multifocal intraocular lenses.

Authors:  Francisco de Asís Bartol-Puyal; Galadriel Giménez; Silvia Méndez-Martínez; Irene Altemir; José Manuel Larrosa; Vicente Polo; Luis Pablo
Journal:  Int Ophthalmol       Date:  2021-05-25       Impact factor: 2.031

2.  Model of the light sword intraocular lens: in-vitro comparative studies.

Authors:  Krzysztof Petelczyc; Andrzej Kolodziejczyk; Narcyz Błocki; Anna Byszewska; Zbigniew Jaroszewicz; Karol Kakarenko; Katarzyna Kołacz; Michał Miler; Alejandro Mira-Agudelo; Walter Torres-Sepúlveda; Marek Rękas
Journal:  Biomed Opt Express       Date:  2019-12-04       Impact factor: 3.732

3.  Visual acuity and defocus curves with six multifocal intraocular lenses.

Authors:  Miguel A Gil; Consuelo Varón; Genis Cardona; José A Buil
Journal:  Int Ophthalmol       Date:  2019-10-17       Impact factor: 2.031

4.  Visual and Refractive Outcomes and Patient Satisfaction Following Implantation of Monofocal IOL in One Eye and ERV IOL in the Contralateral Eye with Mini-Monovision.

Authors:  Sheetal Brar; Sri Ganesh; Raghavender Reddy Arra; Smith Snehal Sute
Journal:  Clin Ophthalmol       Date:  2021-05-04

5.  Visual Performance after a Unilateral or Bilateral Implantation of Enlarged Depth-of-Focus Intraocular Lens in Patients with Cataract: A Prospective Clinical Trial.

Authors:  Se Hyun Choi; Hyo Kyung Lee; Chang Ho Yoon; Mee Kum Kim
Journal:  J Ophthalmol       Date:  2019-03-04       Impact factor: 1.909

6.  Comparison of visual outcomes after bilateral implantation of two intraocular lenses with distinct diffractive optics.

Authors:  André Lins de Medeiros; Flavio Jones Saraiva; Camila Ishii Iguma; Danilo Varela Kniggendorf; Guilherme Alves; Mario Augusto Pereira Dias Chaves; Cesar Vilar; Antonio Francisco Pimenta Motta; Pedro Carlos Carricondo; Celso Takashi Nakano; Walton Nosé; Wilson Takashi Hida
Journal:  Clin Ophthalmol       Date:  2019-08-29

7.  Spectacle Independence And Patient Satisfaction With Pseudophakic Mini-Monovision Using Aberration-Free Intraocular Lens.

Authors:  Tarek Abdelrazek Hafez; Hany Ahmed Helaly
Journal:  Clin Ophthalmol       Date:  2019-10-31

8.  Clinical outcomes with a low add multifocal and an extended depth of focus intraocular lenses both implanted with mini-monovision.

Authors:  Mehmet Orkun Sevik; Semra Akkaya Turhan; Ebru Toker
Journal:  Eye (Lond)       Date:  2021-06-11       Impact factor: 4.456

9.  Monocular Clinical Outcomes and Range of Near Vision following Cataract Surgery with Implantation of an Extended Depth of Focus Intraocular Lens.

Authors:  Rahul T Pandit
Journal:  J Ophthalmol       Date:  2018-12-13       Impact factor: 1.909

Review 10.  A Review of Pharmacological Presbyopia Treatment.

Authors:  Andrzej Grzybowski; Agne Markeviciute; Reda Zemaitiene
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2020 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.